Categories
Prostate cancer

Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future

  • Stang, A. & Jöckel, K. H. The impact of cancer screening on all-cause mortality: what is the best we can expect? Dtsch. Arztebl Int. 115, 481–486 (2018).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Loeb, S. et al. Overdiagnosis and overtreatment of prostate cancer. Eur. Urol. 65, 1046–1055 (2014).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Aizer, A. A. et al. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J. Natl Compr. Cancer Netw. 13, 61–68 (2015).

    Article 

    Google Scholar
     

  • Wang, M. C. et al. Purification of a human prostate specific antigen. Investig. Urol. 17, 159–163 (1979).

    CAS 

    Google Scholar
     

  • Papsidero, L. D. et al. A prostate antigen in sera of prostatic cancer patients. Cancer Res. 40, 2428–2432 (1980).

    CAS 
    PubMed 

    Google Scholar
     

  • Kuriyama, M. et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res. 40, 4658–4662 (1980).

    CAS 
    PubMed 

    Google Scholar
     

  • Kuriyama, M. et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res. 41, 3874–3876 (1981).

    CAS 
    PubMed 

    Google Scholar
     

  • Nadler, R. B., Humphrey, P. A., Smith, D. S., Catalona, W. J. & Ratliff, T. L. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J. Urol. 154, 407–413 (1995).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Ming-Chu, T. Prostate specific antigen (PSA): the historical perspective. MJM https://doi.org/10.26443/mjm.v2i2.564 (1996).

    Article 

    Google Scholar
     

  • Chu, T. M., Wang M. C. & Papsidero, L. Purified human prostate antigen United States Patent and Trademark Office. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=5&f=G&l=50&co1=AND&d=PTXT&s1=316954.AP.&OS=APN/316954&RS=APN/316954 (1984).

  • Stamey, T. A. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909–916 (1987).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Roth, J. A., Gulati, R., Gore, J. L., Cooperberg, M. R. & Etzioni, R. Economic analysis of prostate-specific antigen screening and selective treatment strategies. JAMA Oncol. 2, 890–898 (2016).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Catalona, W. J. et al. Measurement of prostate-specific antigen serum as a screening test for prostate cancer. N. Engl. J. Med. 324, 1156–1161 (1991).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Thompson, I. M., Ernst, J. J., Gangai, M. P. & Spence, C. R. Adenocarcinoma of the prostate: results of routine urological screening. J. Urol. 132, 690–692 (1984).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Schröder, F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320–1328 (2009).

    PubMed 
    Article 

    Google Scholar
     

  • Andriole, G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310–1319 (2009).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Hsing, A. W., Tsao, L. & Devesa, S. S. International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer 85, 60–67 (2000).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • RGHM Cremers, H. E. et al. Prostate cancer: trends in incidence, survival and mortality in the Netherlands, 1989–2006. Eur. J. Urol. 46, 2077–2087 (2010).


    Google Scholar
     

  • Roobol, M. J., Kirkels, W. J. & Schöder, F. H. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int https://doi.org/10.1111/j.1464-410X.2003.04390.x (2004).

    Article 

    Google Scholar
     

  • National Cancer Institute. Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). NIH https://prevention.cancer.gov/major-programs/prostate-lung-colorectal-and-ovarian-cancer-screening-trial (2020).

  • The European Randomized study of Screening for Prostate Cancer. ERSPC Background. ERSPC https://www.erspc.org/prostate-cancer/erspc-background/#study-protocol (2021).

  • Schröder, F. H. & Roobol, M. J. ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur. Urol. 58, 46–52 (2010).

    PubMed 
    Article 

    Google Scholar
     

  • de Koning, H. J. et al. The efficacy of prostate-specific antigen screening: impact of key components in the ERSPC and PLCO trials. Cancer 124, 1197–1206 (2018).

    PubMed 
    Article 

    Google Scholar
     

  • Welch, H. G. & Albertsen, P. C. Reconsidering prostate cancer mortality — the future of PSA screening. N. Engl. J. Med. 382, 1557–1563 (2020).

    PubMed 
    Article 

    Google Scholar
     

  • Culp, M. B., Soerjomataram, I., Efstathiou, J. A., Bray, F. & Jemal, A. Recent global patterns in prostate cancer incidence and mortality rates. Eur. Urol. 77, 38–52 (2020).

    PubMed 
    Article 

    Google Scholar
     

  • Carioli, G. et al. European cancer mortality predictions for the year 2020 with a focus on prostate cancer. Ann. Oncol. 31, 650–658 (2020).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Sung, H. et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clin. 71, 209–249 (2021).


    Google Scholar
     

  • U.S. Preventive Services Task Force. Screening for prostate cancer: recommendation and rationale. Ann. Intern. Med. 137, 915–916 (2002).

    Article 

    Google Scholar
     

  • U.S. Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann. Intern. Med. 149, 185–191 (2008).

    Article 

    Google Scholar
     

  • Moyer, V. A. Screening for Prostate Cancer: US Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157, 120–134 (2012).

    PubMed 
    Article 

    Google Scholar
     

  • Jemal, A., Culp, M. B., Ma, J., Islami, F. & Fedewa, S. A. Prostate cancer incidence 5 years after US Preventive Services Task Force recommendations against screening. J. Natl Inst. 113, 64–71 (2021).

    Article 

    Google Scholar
     

  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Prostate cancer screening with the PSA test. IQWIG https://www.iqwig.de/projekte/s19-01.html (2020).

  • UK National Screening Committee. Screening for prostate cancer. UK National Screening Committee https://view-health-screening-recommendations.service.gov.uk/document/424/download (2020).

  • Ilic, D. et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 362, K3519 (2018).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Tikkinen, K. et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. BMJ 362, K3581 (2018).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Lenzen-Schulte, M. Prostatakrebs-screening: Prüffall PSA-test. Dtsch. Arztebl 117, 1–2 (2020).


    Google Scholar
     

  • Shoag, J. E., Mittal, S., Hu, J. C. & Reevaluating, P. S. A. Testing rates in the PLCO trial. N. Engl. J. Med. 374, 1795–1796 (2016).

    PubMed 
    Article 

    Google Scholar
     

  • Tsodikov, A. et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann. Intern. Med. 167, 449–455 (2017).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Grossman, D. C. et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA 319, 1901–1913 (2018).

    PubMed 
    Article 

    Google Scholar
     

  • European Association of Urology. Archive of the Prostate Cancer guideline. EAU https://uroweb.org/guidelines/archive/prostate-cancer (2020).

  • Martin, R. M. et al. CAP Trial Group effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA 319, 883–895 (2018).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Hugosson, J. et al. Eighteen-year follow-up of the Göteborg randomized population-based prostate cancer screening trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand. J. Urol. 52, 27–37 (2018).

    PubMed 
    Article 

    Google Scholar
     

  • Hugosson, J. et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur. Urol. 76, 43–51 (2019).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Pinsky, P. F. et al. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 123, 854–860 (2019).

    PubMed 
    Article 

    Google Scholar
     

  • Roobol., M. J. Screening for prostate cancer: are organized screening programs necessary? Trans. Androl. Urol. 7, 4–11 (2018).

    Article 

    Google Scholar
     

  • Heijnsdijk, E. A. M. et al. Quality-of-life effects of prostate-specific antigen screening. N. Engl. J. Med. 367, 595–605 (2012).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • RIZIV/INAMI, National Institute for Health and Disability Insurance (NIHDI), Nomenclature of medical acts in Belgium, Chapter V, 11 clinical biology (2021).

  • Heidenreich, A. et al. Early detection of prostate cancer: European Association of Urology recommendation. Eur. Urol. 64, 347–354 (2013).

    PubMed 
    Article 

    Google Scholar
     

  • Yard, D. H. PSA testing: why the U.S. and Europe differ. Renal & Urology News https://www.renalandurologynews.com/home/news/urology/prostate-cancer/psa-testing-why-the-u-s-and-europe-differ/ (2011).

  • Ciatto, S. et al. Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU Int. 92 (Suppl 2), 97–100 (2003).

    PubMed 
    Article 

    Google Scholar
     

  • Pinsky, P. F. et al. Assessing contamination and compliance in the prostate component of the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Clin. Trials 7, 303–311 (2010).

    PubMed 
    Article 

    Google Scholar
     

  • Clift, A. K., Coupland, C. A. C. & Hippisley-Cox, J. Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998–2017. Br. J. Gen. Pract. 71, e157–e165 (2021).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Rijksinstituut voor Ziekte-en Invaliditeitsverzekering (RIZIV/INAMI) statistical department. Statistieken geneeskundige verzorging https://www.riziv.fgov.be/nl/statistieken/geneesk-verzorging/Paginas/default.aspx (2020).

  • Belgian Cancer Registry. Cancer Fact Sheet: Prostate Cancer. Belgian Cancer Registry https://kankerregister.org/media/docs/CancerFactSheets/2019/Cancer_Fact_Sheet_ProstateCancer_2019.pdf (2019).

  • Integraal Kankercentrum Nederland. Prostaatkanker in Nederland. Integraal Kankercentrum Nederland https://iknl.nl/prostaatkanker-in-nederland (2020).

  • Fleshner, K., Carlsson, S. V. & Roobol, M.J. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat. Rev. Urol. 14, 26–37 (2017).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Bandini, M. et al. Increase in the annual rate of newly diagnosed metastatic prostate cancer: a contemporary analysis of the surveillance, epidemiology and end result database. Eur. Urol. Oncol. 1, 314–320 (2018).

    PubMed 
    Article 

    Google Scholar
     

  • Siegel, D. A., O’Neil, M. E., Richards, T. B., Dowling, N. F. & Weir, H. K. Prostate cancer incidence and survival, by stage and race/ethnicity — United States, 2001–2017. MMWR Morb. Mortal. Wkly. Rep. 69, 1473–1480 (2020).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer 103, 356–387 (2018).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Sharma, V., Venkataramana, A., Comulada, W. S., Litwin, M. S. & Saigal, C. Association of reductions in PSA screening across states with increased metastatic prostate cancer in the United States. J. Clin. Oncol. 39, 228 (2021).

    Article 

    Google Scholar
     

  • Prostate Cancer UK. We call on UK to step up as new figures show prostate cancer now a bigger killer than breast cancer. Prostate Cancer UK https://prostatecanceruk.org/about-us/news-and-views/2018/2/we-call-on-uk-to-step-up-as-new-figures-show-prostate-cancer-now-a-bigger-killer-than-breast-cancer (2018).

  • Butler, E. B., Kelly, S. P., Coupland, V. H., Rosenberg, P. S. & Cook, M. B. Fatal prostate cancer incidence trends in the United States and England by race, stage, and treatment. Br. J. Cancer 123, 487–494 (2020).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Arnsrud Godtman, R., Holmberg, E., Lilja, H., Stranne, J. & Hugosson, J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur. Urol. 68, 354–360 (2015).

    PubMed 
    Article 

    Google Scholar
     

  • Pickles, K., Carter, S. M. & Rychetnik, L. C. Doctors’ approaches to PSA testing and overdiagnosis in primary healthcare: a qualitative study. BMJ Open 5, e006367 (2015).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Guessous, I. et al. Prostate cancer screening in Switzerland: 20-year trends and socioeconomic disparities. Prev. Med. 82, 83–91 (2016).

    PubMed 
    Article 

    Google Scholar
     

  • Jessen, K., Sondergaard, J., Veldt Larsen, P. & Thomsen, J. L. Danish general practitioners’ use of prostate-specific antigen in opportunistic screening for prostate cancer: a survey comprising 174 GPs. Int. J. Fam. Med. https://doi.org/10.1155/2013/540707 (2013).

    Article 

    Google Scholar
     

  • Matti, B. & Zargar-Shoshtari, K. Opportunistic prostate cancer screening: a population-based analysis. Urol. Oncol. 38, 393–400 (2020).

    PubMed 
    Article 

    Google Scholar
     

  • Fossa, S. D. & Eri, L. M. Norske legers rutiner for opportunistisk screening for prostatekreft. Tidsskr. Nor. Laegeforen. 199, 3572–3576 (1999).


    Google Scholar
     

  • Bertuccio, P. et al. Mortality trends from urologic cancers in Europe over the period 1980–2017 and a projection to 2025. Eur. Urol. Oncol. 4, 677–696 (2021).

    PubMed 
    Article 

    Google Scholar
     

  • Patasius, A. & Smailyte, G. Changing incidence and stage distribution of prostate cancer in a Lithuanian population — evidence from national PSA-based screening program. Int. J. Environ. Res. Public Health 16, 4856 (2019).

    PubMed Central 
    Article 

    Google Scholar
     

  • Patasius, A. et al. Prostate cancer incidence and mortality in the Baltic states Belarus, the Russian Federation and Ukraine. BMJ Open. 9, e031856 (2019).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Moyer, V. A. & U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157, 120–134 (2012).

    Article 

    Google Scholar
     

  • Basch, E. et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion. J. Clin. Oncol. 30, 3020–3025 (2012).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Wolf, A. M. et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J. Clin. 60, 70–98 (2010).

    PubMed 
    Article 

    Google Scholar
     

  • Carter, H. B. et al. Early detection of prostate cancer: AUA Guideline. J. Urol. 190, 419–426 (2013).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • National Comprehensive Cancer Network. Prostate Cancer Early Detection. NCCN http://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf (2021).

  • Mottet, N. et al. EAU-EANM-ESTRO-SIOG Guidelines on Prostate Cancer — 2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 79, 243–262 (2021).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Rommel, F. M. et al. The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in community based urology practice. J. Urol. 151, 88–93 (1994).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Nordström, T., Akre, O., Aly, M., Grönberg, H. & Eklund, M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis. 21, 57–63 (2018).

    PubMed 
    Article 

    Google Scholar
     

  • Abd-Alazeez, M. et al. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level — can it rule out clinically significant prostate cancer? Urol. Oncol. 32, 45.e17–e22 (2014).

    Article 

    Google Scholar
     

  • Stichting Wetenschappelijk Onderzoek Prostaatkanker, Reeuwijk. Your Prostate Cancer Risk Calculator. prostatecancer-riskcalculator.com https://www.prostatecancer-riskcalculator.com/assess-your-risk-of-prostate-cancer (2022).

  • Ankerst, D. P. et al. The Prostate Cancer Prevention Trial Risk Calculator 2.0 for the prediction of low- versus high-grade prostate cancer. Urology 83, 1362–1367 (2014).

    PubMed 
    Article 

    Google Scholar
     

  • Roobol., M. J. Rescreening policies and risk calculator. J. Nat. Rev. Urol. 11, 429–430 (2014).

    Article 

    Google Scholar
     

  • Louie, K. S., Seigneurin, A., Cathcart, P. & Sasieni, P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann. Oncol. 26, 848–864 (2015).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Stabile, A. et al. Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nat. Rev. Urol. 17, 41–61 (2020).

    PubMed 
    Article 

    Google Scholar
     

  • Alberts, A. R. et al. Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging improving the Rotterdam European Randomized study of screening for prostate cancer risk calculators. Eur. Urol. 75, 310–318 (2019).

    PubMed 
    Article 

    Google Scholar
     

  • Mottet N, et al. EAU guidelines: EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer (EAU Guidelines Office, 2019).

  • Van Poppel, H. et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021. Eur. Urol. 80, 703–711 (2021).

    PubMed 
    Article 

    Google Scholar
     

  • Schröder, F. H. et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European randomized study of screening for prostate cancer (ERSPC). Eur. Urol. 62, 745–752 (2012).

    PubMed 
    Article 

    Google Scholar
     

  • Vickers, A. J. et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European randomized study of prostate cancer screening in Göteborg, Sweden. BMC Med. 6, 19 (2008).

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar
     

  • Jansen, F. H. et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur. Urol. 57, 921–927 (2010).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Osses, D. F., Roobol, M. J. & Schoots., I. G. Prediction medicine: biomarkers, risk calculators and magnetic resonance imaging as risk stratification tools in prostate cancer diagnosis. Int. J. Mol. Sci. 20, 1637 (2019).

    CAS 
    PubMed Central 
    Article 

    Google Scholar
     

  • Roobol, M. J. et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur. Urol. 61, 577–583 (2012).

    PubMed 
    Article 

    Google Scholar
     

  • Pereira-Azevedo, N. et al. Prospective evaluation on the effect of interobserver variability of digital rectal examination on the performance of the Rotterdam prostate cancer risk calculator. Int. J. Urol. 24, 826–832 (2017).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Ankerst, D. P. et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology 83, 1362–1368 (2014).

    PubMed 
    Article 

    Google Scholar
     

  • Mannaerts, C. K. et al. Prostate cancer risk assessment in biopsy-naive patients: the Rotterdam prostate cancer risk calculator in multiparametric magnetic resonance imaging-transrectal ultrasound (TRUS) fusion biopsy and systematic TRUS biopsy. Eur. Urol. Oncol. 1, 109–117 (2018).

    PubMed 
    Article 

    Google Scholar
     

  • Weinreb, J. C. et al. PI-RADS prostate imaging-reporting and data system: 2015, version 2. Eur. Urol. 69, 16–40 (2016).

    PubMed 
    Article 

    Google Scholar
     

  • Pagniez, M. A. et al. Predictive factors of missed clinically significant prostate cancers in men with negative magnetic resonance imaging: a systematic review and meta-analysis. J. Urol. 204, 24–32 (2020).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Ullrich, T. et al. Risk stratification of equivocal lesions on multiparametric magnetic resonance imaging of the prostate. J. Urol. 199, 691–698 (2018).

    PubMed 
    Article 

    Google Scholar
     

  • Shill, D. K., Roobol, M. J., Ehdaie, B., Vickers, A. J. & Carlsson, S. V. Active surveillance for prostate cancer. Trans. Androl. Urol. 10, 2809–2819 (2021).

    Article 

    Google Scholar
     

  • Desai, M. M. et al. Trends in incidence of metastatic prostate cancer in the US. JAMA Netw. Open 5, e222246 (2022).

    PubMed 
    Article 

    Google Scholar
     

  • Ross, L. E., Hall, I. J., Howard, D. L., Rim, S. H. & Richardson, L. C. Primary care physicians beliefs about prostate-specific antigen evidence uncertainty, screening efficacy, and test use. J. Natl Med. Assoc. 110, 491–500 (2018).

    PubMed 

    Google Scholar
     

  • Drummond, F. J., Carsin, A.-E., Sharp, L. & Comber, H. Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners. BMC Fam. Pract. 10, 1–12 (2009).

    Article 

    Google Scholar
     

  • Kappen, S., Jurgens, V., Freitag, M. H. & Winter, A. Early detection of prostate cancer using prostate-specific antigen testing: an empirical evaluation among general practitioners and urologists. Cancer Manag. Res. 11, 3079–3097 (2019).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Cajka., P. Issues of an ageing population in European Union. Environ. Sci. Eng. B. 1, 966–970 (2012).


    Google Scholar
     

  • Rawla., P. Epidemiology of prostate cancer. World J. Urol. 10, 63–89 (2019).

    CAS 

    Google Scholar
     

  • Eurostat. Ageing Europe — looking at the lives of older people in the EU — 2019 edition. (2019)

  • Getaneh, A. M. et al. Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: a micro-simulation study of 230 scenarios. Cancer Med. 9, 7742–7750 (2020).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Carlsson, S. V. et al. Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: a microsimulation screening analysis. Cancer 122, 3386–3393 (2016).

    PubMed 
    Article 

    Google Scholar
     

  • Sanghera, S. et al. Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models. BMC Cancer 18, 84 (2018).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Callender, T. et al. Benefit, harm, and cost-effectiveness associated with magnetic resonance imaging before biopsy in age-based and risk-stratified screening for prostate cancer. JAMA Netw. Open 4, e2037657 (2021).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • de Rooij, M. et al. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. Eur. Urol. 66, 430–436 (2014).

    PubMed 
    Article 

    Google Scholar
     

  • Yusuf, S. et al. Modifiable risk factors, cardiovascular disease, and mortality in 155722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 395, 795–808 (2020).

    PubMed 
    Article 

    Google Scholar
     

  • Grönberg, H. et al. Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 16, P1667–P1676 (2015).

    Article 

    Google Scholar
     

  • Mortezavi, A. et al. Head-to-head comparison of conventional, and image- and biomarker-based prostate cancer risk calculators. Eur. Urol. Focus. 7, 546–553 (2021).

    PubMed 
    Article 

    Google Scholar
     

  • Eklund, M. et al. The Stockholm-3 (STHLM3) model can improve prostate cancer diagnostics in men aged 50–69 yr compared with current prostate cancer testing. Eur. Urol. Focus. 4, 707–710 (2018).

    PubMed 
    Article 

    Google Scholar
     

  • Eklund, M. et al. MRI-targeted or standard biopsy in prostate cancer screening. N. Engl. J. Med. 385, 908–920 (2021).

    PubMed 
    Article 

    Google Scholar
     

  • Twilt, J. J. et al. Artificial intelligence based algorithms for prostate cancer classification and detection on magnetic resonance imaging: a narrative review. Diagnostics 11, 959 (2021).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Knaapila, J. et al. Negative predictive value of biparametric prostate magnetic resonance imaging in excluding significant prostate cancer: a pooled data analysis based on clinical data from four prospective, registered studies. Eur. Urol. Focus. 7, 522–531 (2021).

    PubMed 
    Article 

    Google Scholar
     

  • Wallström, J. et al. Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Goteborg prostate cancer screening 2 trial. Eur. Radiol. 31, 8692–8702 (2021).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Remmers, S. & Roobol, M. J. Personalized strategies in population screening for prostate cancer. Int. J. Cancer 147, 2977–2987 (2020).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Van Poppel, H. et al. A European model for an organised risk-stratified early detection programme for prostate cancer. Eur. Urol. Oncol. 5, P731–P739 (2021).

    Article 

    Google Scholar
     

  • European Association of Urology. Information for patients: prostate cancer. EAU https://patients.uroweb.org/wp-content/uploads/2018/12/12-July-2018_Prostate-cancer.pdf (2014).

  • National Health Service. PSA testing and prostate cancer: advice for well men aged 50 and over. NHS https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/856976/PSA_testing_for_prostate_cancer_information_for_well_men.pdf (2020).

  • Xavier, R. et al. Risk prediction tools in cardiovascular disease prevention: a report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). Eur. J. Prev. Cardiol. 26, 1534–1544 (2019).

    Article 

    Google Scholar
     

  • Mishra, S. C. A discussion on controversies and ethical dilemmas in prostate cancer screening. J. Med. Ethics 47, 152–158 (2021).

    Article 

    Google Scholar
     

  • Légaré, F. & Thompson-Leduc, P. Twelve myths about shared decision making. Patient Educ. Couns. 96, 281–286 (2014).

    PubMed 
    Article 

    Google Scholar
     

  • Roobol, M. J. Active surveillance for prostate cancer — will the discoveries of the last 5 years change the future? Transl. Androl. Urol. 10, 2828–2831 (2021).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Leave a Reply